G
Gary Burgess
Researcher at Pfizer
Publications - 17
Citations - 3275
Gary Burgess is an academic researcher from Pfizer. The author has contributed to research in topics: Sildenafil & Liver transplantation. The author has an hindex of 8, co-authored 16 publications receiving 3082 citations.
Papers
More filters
Journal ArticleDOI
Sildenafil citrate therapy for pulmonary arterial hypertension.
Nazzareno Galiè,Hossein Ardeschir Ghofrani,Adam Torbicki,Robyn J. Barst,Lewis J. Rubin,David B. Badesch,Thomas R. Fleming,Tamiza Parpia,Gary Burgess,Angelo Branzi,Friedrich Grimminger,Marcin Kurzyna,Gérald Simonneau +12 more
TL;DR: Among the 222 patients completing one year of treatment with sildenafil monotherapy, the improvement from baseline at one year in the distance walked in six minutes was 51 m, and the incidence of clinical worsening did not differ significantly between the patients treated with s Bildenafils and those treated with placebo.
Journal ArticleDOI
Addition of Sildenafil to Long-Term Intravenous Epoprostenol Therapy in Patients with Pulmonary Arterial Hypertension: A Randomized Trial
G. Simonneau,Lewis J. Rubin,Nazzareno Galiè,Robyn J. Barst,Thomas R. Fleming,Adaani E. Frost,Peter J. Engel,Mordechai R. Kramer,Gary Burgess,Lorraine Collings,Nandini Cossons,Olivier Sitbon,David B. Badesch +12 more
TL;DR: A 16-week, double-blind, placebo-controlled, parallel-group study as discussed by the authors investigated the effect of adding oral sildenafil to long-term intravenous epoprostenol in patients with pulmonary arterial hypertension.
Journal Article
Sildenafil for pulmonary arterial hypertension associated with connective tissue disease.
David B. Badesch,Nicholas S. Hill,Gary Burgess,Lewis J. Rubin,Robyn J. Barst,Nazzareno Galiè,Gérald Simonneau +6 more
TL;DR: In patients with PAH-CTD, sildenafil improves exercise capacity, hemodynamic measures, and functional class after 12 weeks of treatment.
Journal ArticleDOI
Mutual pharmacokinetic interactions between steady-state bosentan and sildenafil
TL;DR: There is a mutual pharmacokinetic interaction between bosentan and sildenafil that may influence the dosage of each drug in a combination treatment, and further trials in patients with PAH are needed.
Journal ArticleDOI
Digital image analysis of collagen assessment of progression of fibrosis in recurrent HCV after liver transplantation
Pinelopi Manousou,Andrew K. Burroughs,Emmanuel T. Sochatzis,Grazia Isgro,Andrew M. Hall,A Green,Vincenza Calvaruso,Vincenza Calvaruso,G. Ma,Jeremy D. Gale,Gary Burgess,James O'Beirne,David Patch,Douglas Thorburn,Gioacchino Leandro,Amar P. Dhillon +15 more
TL;DR: CPA fibrosis progression rate is a better predictor of clinical outcome than progression by Ishak stage, and histological de novo hepatitis, older donor age and non-use/discontinuation of azathioprine are associated with rapid Fibrosis progression in recurrent HCV chronic hepatitis after liver transplantation.